These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 3379369)

  • 21. [Prevention and treatment of coronary heart disease: lowering LDL, increasing HDL or monitoring both?].
    Windler E
    Internist (Berl); 1996 Jun; 37(6):643-6. PubMed ID: 8768000
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of hypercholesterolemia in patients with known coronary artery disease.
    Schlant RC
    Heart Dis Stroke; 1993; 2(5):373-6. PubMed ID: 8137037
    [No Abstract]   [Full Text] [Related]  

  • 23. New trends in lipid management: eight cases to consider.
    Smith DA
    Mt Sinai J Med; 2005 Mar; 72(2):90-9. PubMed ID: 15770338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Time- and dose-dependent effect of psyllium on serum lipids in mild-to-moderate hypercholesterolemia: a meta-analysis of controlled clinical trials.
    Wei ZH; Wang H; Chen XY; Wang BS; Rong ZX; Wang BS; Su BH; Chen HZ
    Eur J Clin Nutr; 2009 Jul; 63(7):821-7. PubMed ID: 18985059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low density lipoprotein cholesterol lowering: are the treatment guidelines still appropriate?
    Deslypere JP
    Int J Clin Pract; 2000 Jun; 54(5):307-13. PubMed ID: 10954957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low density lipoprotein cholesterol: is lower better?
    Leiter LA
    Can J Cardiol; 2000 Jan; 16 Suppl A():20A-2A. PubMed ID: 10653927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pravastatin multicenter clinical trial in patients with hypercholesterolemia and multiple risk factors].
    Barrett e Pesquisadores AC
    Arq Bras Cardiol; 1997 Jan; 68(1):65-71. PubMed ID: 9334463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
    Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
    Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Examination of encapsulated phytosterol ester supplementation on lipid indices associated with cardiovascular disease.
    Earnest CP; Mikus CR; Lemieux I; Arsenault BJ; Church TS
    Nutrition; 2007 Sep; 23(9):625-33. PubMed ID: 17644340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypercholesterolemia. Is lipid-lowering worthwhile for older patients?
    Deedwania PC
    Geriatrics; 2000 May; 55(5):22-8. PubMed ID: 10826262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.
    Devroey D; Velkeniers B; Duquet W; Betz W
    Int J Cardiol; 2005 May; 101(2):231-5. PubMed ID: 15882669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare?
    Gotto AM; Kuller LH
    Circulation; 2002 Jan; 105(2):136-9. PubMed ID: 11790688
    [No Abstract]   [Full Text] [Related]  

  • 34. Primary and secondary prevention of coronary heart disease. Evidence offers multiple strategies.
    Lynn MM
    Adv Nurse Pract; 2000 Jun; 8(6):36-41; quiz 42-3. PubMed ID: 15658206
    [No Abstract]   [Full Text] [Related]  

  • 35. [The lowering of serum cholesterol in the prevention of coronary disease (part 1). The Canadian Study Group for Periodic Medical Examinations].
    Union Med Can; 1994 Apr; 123(4):249-58. PubMed ID: 8203048
    [No Abstract]   [Full Text] [Related]  

  • 36. Attitude changes of general practitioners towards lowering LDL cholesterol.
    Strandberg TE; Pitkänen A; Larjo P; Hirvonen P; Kohvakka A
    J Cardiovasc Risk; 1998 Feb; 5(1):43-6. PubMed ID: 9816555
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of serum cholesterol and cholesterol subfractions on restenosis following successful coronary intervention.
    Violaris AG; Ismail TF; El-Gendi H; Foale RA
    Semin Interv Cardiol; 1999 Sep; 4(3):111-9. PubMed ID: 10545617
    [No Abstract]   [Full Text] [Related]  

  • 39. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
    Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
    Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.